<qa>  What is the name of the subject that must be aware of the risks and benefits of switching theirInhaled Corticosteroid Total Daily Dose Beclomethasone dipropionate 420mcg Beclomethasone dipropionate HFA 240mcg Budesonide 400mcg Flunisolide 1000mcg Fluticasone propionate inhalation aerosol 220mcg Fluticasone propionate inhalation powder 250mcg Mometasone furoate 220mcg Triamcinolone acetonide 1000mcg Subjects taking ADVAIR 10050mcg BID are eligible to replace ADVAIR with FLOVENT HFA 110mcg BID for 14 days prior to Visit 1. This change will be at the Investigators clinical discretion, taking each individuals current and past asthma stability into account. The subject must be aware of the risks and benefits of switching their medication and acknowledge this by signing an informed consent prior to any change in the subjects medication regimen. 